HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Sudarsanam, T D Articles by John, G T Search for Related Content PubMed PubMed Citation Articles by Sudarsanam, T D Articles by John, G T

Leflunomide: a possible alternative for gangciclovir sensitive and resistant cytomegalovirus infections

¹ Department of Medicine, CMC, Vellore, India
² Department of Microbiology, CMC, Vellore
³ Department of Nephrology, CMC, Vellore

Correspondence to:
Correspondence to:
Dr T D Sudarsanam
Department of Medicine, CMC, Vellore, 632004, India; thambu{at}cmcvellore.ac.in

The search for newer more cost effective treatments for infectious diseases remains a challenge. Cytomegalovirus (CMV) infection, which is especially common in the immunosupressed, is an important challenge for treating physicians. Gangciclovir’s cost is a major hurdle in developing countries. Leflunomide is cheaper and is easily given orally. It works by a novel mechanism inhibiting virion assembly. It also has immunosuppressive properties. It and has been shown to be effective in both gangciclovir sensitive as well as resistant cases of CMV infection. Given these considerations we believe that leflunomide is an exiting new drug for CMV infection. However, hepatotoxicity and teratogenicity are known side effects. The exact dose and duration of treatment for CMV infection, for secondary prophylaxis, and in situations of gangciclovir resistance need further study.

Keywords: leflunomide; cytomegalovirus; infection; gangciclovir; resistance